Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 6Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma 27Breast Neoplasms 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Large B-Cell, Diffuse 19Ovarian Neoplasms 14Neoplasms 14Lymphoma 12Burkitt Lymphoma 11Neoplasm Metastasis 10Recurrence 9Lymphoma, Non-Hodgkin 9Triple Negative Breast Neoplasms 8Neuroblastoma 7Fallopian Tube Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell, Peripheral 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, Follicular 5Lymphoma, B-Cell 5Leukemia 5Hodgkin Disease 5Unspecified Adult Solid Tumor, Protocol Specific 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Multiple Myeloma 4Lymphoma, T-Cell 4Lung Neoplasms 4Liposarcoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Biphenotypic, Acute 4

Interventions

oblimersen 1Razoxane 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Exercise 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Carvedilol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cardiotoxicity × Doxorubicin × Clear all
NCT00039481 2013-01-17

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡